logo-loader
viewMaxCyte Inc

Maxcyte deal with Allogene Therapeutics 'a clear endorsement' of its technology

Proactive Research analyst Emma Ulker says MaxCyte’s (LON:MXCT) deal with clinical-stage industry leader Allogene Therapeutics (NASDAQ:ALLO) is a clear endorsement of the features of its Flow Electroporation technology.

Described by Allogene as the ‘industry standard’, MXCT’s Flow Electroporation has been chosen to improve yield and efficiency of its lead clinical programmes.  

Click here to read Emma Ulker's update on MaxCyte Inc "Allogene deal is validation for new CAR-T wave"

Quick facts: MaxCyte Inc

Price: 294 GBX

AIM:MXCT
Market: AIM
Market Cap: £226.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc 'demonstrating outstanding progress' as first half revenues...

Proactive Research analyst Emma Ulker discusses MaxCyte Inc's (LON:MXCT) first half trading update in which it revealed revenues grew by 30% to US$10.9mln and that its research and development operation's expected to be self-funded by the end of the year. Ulker says trading reflected the solid...

3 weeks ago

2 min read